Primer: Sciclone Pharmaceuticals (6600 HK) - Mar 2026
SciClone Pharmaceuticals is a biopharmaceutical company with a strong focus on the Chinese market, leveraging an integrated platform for...
155 Views
𝛼SK or SearchENTITY
SciClone Pharmaceuticals (SCICLONE HK)
SciClone Pharmaceuticals (SCICLONE HK)
108
Analysis
Health Care • China
SciClone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for oncology and severe infection in Mainland China and internationally. Its portfolio includes proprietary product Zadaxin, used for hepatitis B, hepatitis C, and certain cancers, as well as in-licensed products like Zometa, DANYELZA, and Angiomax. The company was founded in 1990 and is headquartered in Shanghai, China.
morex